Molecular pathology of posttransplantation lymphoproliferative disorders

被引:0
|
作者
Chadburn, A
Cesarman, E
Knowles, DM
机构
关键词
posttransplantation lymphoproliferative disorder; immunosuppression; Epstein-Barr virus;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Posttransplantation lymphoproliferative disorders (PT-LPDs) represent a heterogeneous group of Epstein-Barr virus (EBV) associated lymphoid proliferations occurring in the setting of immunosuppression associated with solid organ transplantation. Some PT-LPDs regress after a reduction in immunosuppression, whereas others progress despite aggressive therapy. Previously defined histopathologic categories do not correlate with clonality, and neither histopathology nor clonality has reliably predicted their clinical behavior. Recently, correlative clinical, morphological, and molecular genetic analysis has suggested that PT-LPDs are divisible into three distinct clinically relevant categories as follows: (1) plasmacytic hyperplasia: most commonly arise in the oropharynx or lymph nodes, are nearly always polyclonal, usually contain multiple EBV infectious events or only a minor cell population infected by a single form of EBV, and lack oncogene or tumor suppressor gene alterations; (2) polymorphic lymphoproliferative disorders: may arise in lymph nodes or extranodal sites including the gastrointestinal tract and lungs, are nearly always monoclonal based on the presence of clonal immunoglobulin gene rearrangements, usually contain a single form of EBV, and lack oncogene or tumor suppressor gene alterations; and (3) malignant lymphoma or multiple myeloma: present with widely disseminated disease frequently including the bone marrow, are monoclonal based on clonal immunoglobulin gene rearrangements, contain a single form of EBV, and contain alterations of one or more oncogenes or tumor suppressor genes (c-myc, ras, p53). Thus, protooncogene and tumor suppressor gene alterations appear to be associated with disease progression and an often fatal clinical outcome. Furthermore, multiple PT-LPD lesions occurring in the same individual but in multiple anatomic sites, either simultaneously or dysynchronously over time, may show distinct clonal immunoglobulin gene rearrangement patterns and evidence of infection by different forms of EBV, suggesting that each lesion represents a distinct clonal neoplasm that may show distinctive clinical behavior. Therefore, whenever possible, a biopsy of each one of the several PT-LPD lesions occurring in an individual should be obtained to derive a true assessment of the pathobiological nature and clinical aggressiveness of an individual's disease. Copyright (C) 1997 by W.B. Saunders Company.
引用
收藏
页码:15 / 26
页数:12
相关论文
共 50 条
  • [31] Therapeutic experiences of 21 patients with posttransplantation lymphoproliferative disorders (PT-LPD)
    Milpied, N
    Lamy, T
    Deconinck, E
    Colombat, P
    Delwail, V
    Desablens, B
    Foussard, C
    Harousseau, JL
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 237 - 237
  • [32] Conjunctival posttransplantation lymphoproliferative disorder
    Walton, R. Christopher
    Onciu, Mihaela M.
    Irshad, Farhan A.
    Wilson, Terry D.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2007, 143 (06) : 1050 - 1051
  • [33] POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDERS TREATED WITH CYCLOPHOSPHAMIDE-DOXORUBICIN-VINCRISTINE-PREDNISONE CHEMOTHERAPY
    GARRETT, TJ
    CHADBURN, A
    BARR, ML
    DRUSIN, RE
    CHEN, JM
    SCHULMAN, LL
    SMITH, CR
    REISON, DS
    ROSE, EA
    MICHLER, RE
    KNOWLES, DM
    CANCER, 1993, 72 (09) : 2782 - 2785
  • [34] Expression of p16/INK4a in posttransplantation lymphoproliferative disorders
    Martin, A
    Baran-Marzak, F
    El Mansouri, S
    Legendre, C
    Leblond, V
    Charlotte, F
    Davi, F
    Canioni, D
    Raphaël, M
    AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (05): : 1573 - 1579
  • [35] Extramedullary plasmacytoma-like posttransplantation lymphoproliferative disorders: Clinical and pathologic features
    Richendollar, B.
    Hsi, E. D.
    Cook, J. R.
    LABORATORY INVESTIGATION, 2008, 88 : 271A - 271A
  • [36] Molecular genetics and lymphoproliferative disorders
    Lust, JA
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1996, 10 (06) : 359 - 367
  • [37] Posttransplantation lymphoproliferative disorders in renal transplant recipients: Report of over 20 years of experience
    Saadat, A.
    Einollahi, B.
    Ahmadzad-Asl, M. A.
    Moradi, M.
    Nafar, M.
    Pourfarziani, V.
    Firoozan, A.
    Porrezagholi, F.
    Davoudi, F.
    TRANSPLANTATION PROCEEDINGS, 2007, 39 (04) : 1071 - 1073
  • [38] Donor or recipient origin of posttransplantation lymphoproliferative disorders: The traces of the Epstein-Barr virus
    Volk, HD
    Babel, N
    Reinke, P
    TRANSPLANTATION, 2001, 72 (03) : 361 - 362
  • [39] Posttransplantation Lymphoproliferative Disease Treated by Retransplantation
    Abrahamsen, Ingerid Weum
    Gronvold, Bjorn Christer
    Inderberg, Else Marit
    Mensali, Nadia
    Mattsson, Jonas
    Gedde-Dahl, Tobias
    CASE REPORTS IN IMMUNOLOGY, 2020, 2020
  • [40] Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients
    Beynet, DP
    Wee, SA
    Horwitz, SS
    Kohler, S
    Horning, S
    Hoppe, R
    Kim, YH
    ARCHIVES OF DERMATOLOGY, 2004, 140 (09) : 1140 - 1146